2025/06/30 by Weixin Chen, Yuan Xu, Hongsheng Liu · 1 voice
Biochemistry, Genetics and Molecular Biology · Medicine · #Lung Cancer Treatments and Mutations #Metabolomics and Mass Spectrometry Studies #Nutrition, Genetics, and Disease
paper · pdf · doi:10.14218/csp.2025.00005
openalex publication_date 2025/06/30 · openalex created_date 2025/10/10 · openalex updated_date 2026/06/11
Lung cancer remains the leading cause of cancer-related mortality worldwide, with marked phenotypic differences observed among its major histological subtypes, adenocarcinoma (ADC), squamous cell carcinoma (SCC), and small cell lung cancer (SCLC), in both clinical presentation and therapeutic response. In recent years, metabolomics has emerged as a powerful tool for studying cancer metabolic reprogramming, providing new insights into the metabolic distinctions among lung cancer subtypes. This review summarizes recent research advances in the metabolomics of ADC, SCC, and SCLC. Studies have revealed that ADC and SCC display distinct metabolic profiles in lipid metabolism, amino acid metabolism, and cell membrane synthesis, while SCLC demonstrates a unique metabolic pattern. Through metabolomic technologies, particularly mass spectrometry and liquid chromatography, it is possible to effectively differentiate lung cancer subtypes and identify potential biomarkers for early diagnosis and personalized treatment. This review also explores the clinical potential of metabolomics in lung cancer, emphasizing its critical role in early diagnosis and subtype stratification. These methodological advances establish a robust foundation for precision oncology paradigms in thoracic malignancies.